Evidence map›Paper›PMID 23812602›Full record

ReviewChromosoma2013

Starting and stopping SUMOylation. What regulates the regulator?

Felicity Z Watts

Abstract readReview
PubMed Publisher
In one paragraph

Review in Chromosoma, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. SUMO and the robustness of cancer.Nature reviews. Cancer · 2017
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Felicity Z WattsGenome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton, BN1 9QG, UK, f.z.watts@sussex.ac.uk.
University of Sussex · GB

Funding

Cancer Research UK 11978Medical Research Council G0500308
6 · The paper itself

Abstract

A large number of proteins are modified post-translationally by the ubiquitin-like protein (Ubl) SUMO. This process, known as sumoylation, regulates the function, localisation and activity of target proteins as part of normal cellular metabolism, e.g., during development, and through the cell cycle, as well as in response to a range of stresses. In order to be effective, the sumoylation pathway itself must also be regulated. This review describes how the SUMOylation process is regulated. In particular, regulation of the SUMO conjugation and deconjugation machinery at the level of transcription and by post-translational modifications is discussed.

Indexed as

AcetylationAnimalsGene Expression RegulationHumansPhosphorylationProtein TransportReactive Oxygen SpeciesSaccharomyces cerevisiaeSignal TransductionSmall Ubiquitin-Related Modifier ProteinsSumoylationUbiquitin-Activating EnzymesUbiquitin-Conjugating EnzymesReactive Oxygen SpeciesSmall Ubiquitin-Related Modifier ProteinsUbiquitin-Activating EnzymesUbiquitin-Conjugating Enzymes

Identifiers

PMID23812602
OpenAlexW2015868577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.